CN106580967A - Medicine composition for treating KOA (knee osteoarthritis) - Google Patents
Medicine composition for treating KOA (knee osteoarthritis) Download PDFInfo
- Publication number
- CN106580967A CN106580967A CN201710087011.1A CN201710087011A CN106580967A CN 106580967 A CN106580967 A CN 106580967A CN 201710087011 A CN201710087011 A CN 201710087011A CN 106580967 A CN106580967 A CN 106580967A
- Authority
- CN
- China
- Prior art keywords
- halogen
- independently selected
- knee joint
- medicine composition
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
Abstract
The invention relates to medicine composition for treating KOA (knee osteoarthritis). The medicine composition comprises a compound shown in a formula in the specification or pharmaceutically acceptable salt of the compound and a pharmaceutically acceptable carrier, wherein R1 is independently selected from H or halogen; R2 is independently selected from H, alkyl or halogen. The medicine composition can relieve knee pain and improve the joint motion function and has a definite curative effect and a remarkable treatment function on KOA.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of medicine for treating knee joint osseous arthritiies
Compositionss.
Background technology
Knee joint joint arthritis are the chronic joints that a kind of degeneration with articular cartilage, destruction and hyperosteogeny are characterized
Disease, also known as Knee Arthritis, senile gonarthritis.It is a kind of chronic joint diseases, and its main change is that knee joint is closed
The degeneration and insecondary hyperosteogeny of section cartilage surface.Main performance is that arthralgia and activity are dumb, and x-ray performance is closed
Section gap turn narrow, subchondral bone matter is fine and close, bone trabecula fracture, there is hardening and cystis degeneration.Joint margins have lip sample hypertrophy.Later stage bone
End deformation, articular surface is uneven.Intraarticular cartilage is peeled off, and sclerotin fragmentation enters joint, forms articular mobile corpus.Clinically
Fallen ill with person in middle and old age most common, women is more than male.Pathological characteristics are the degeneration of focal articular cartilage, subchondral bone matter
Become close (hardening) marginality bone cartilage hyperosteogeny to be formed and joint deformity.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating knee joint osseous arthritiies.
In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition for treating knee joint osseous arthritiies,
Described pharmaceutical composition includes the compound or its pharmaceutically acceptable salt of following formula and pharmaceutically acceptable carrier：
Wherein
R1 independently selected from：H or halogen；
R2 independently selected from：H, alkyl or halogen.
It is highly preferred that R1 is Cl.
It is highly preferred that R2 is CH3。
The present invention also provides purposes of the compound in the medicine for preparing treatment knee joint osseous arthritiies, the compound
With having structure：
Wherein
R1 independently selected from：H or halogen；
R2 independently selected from：H, alkyl or halogen.
It is highly preferred that R1 is Cl.
It is highly preferred that R2 is CH3。
Medicine of the present invention can alleviate the gonalgia, improve joint movement function, determined curative effect, to treating knee joint bone
Property arthritis play obvious action.
Specific embodiment
In order that the objects, technical solutions and advantages of the present invention become more apparent, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that specific embodiment described herein is not used to only to explain the present invention
Limit the present invention.
The sign of the medicine of the present invention of experimental example 1
1H-NMR(CDCl3)δ:7.74 (1H, d, J=2.5Hz), 7.58 (2H, dt, J=9.5,2.6Hz), 7.41 (2H,
Dt, J=9.4,2.5Hz), and 7.34-7.30 (1H, m), 7.28 (1H, d, J=7.6Hz), 7.15 (1H, d, J=7.3Hz), 6.19
(1H, d, J=2.5Hz), 4.33 (2H, s), 3.53 (3H, s), 2.47 (3H, s).
The medicine of the present invention of experimental example 2 is for the therapeutic effect of knee joint osseous arthritiies
Knee osteoarthritis model and administration
By cleaning grade (SPF) male Wistar rat (the Mus age 5-6 months, weight 170.0 ± 20.5) be divided into 4 groups：Normally
Matched group (Normal control group, NC), model control group (Model control group, MC), glucosamine
Matched group (Glucosamine control group, GS), medicine group of the present invention.10 per group.In addition to Normal group, to
The right knee joint of remaining each group rat injects the L-Cysteine of 4 weight % Papain enzyme aqueous solution 10 μ L and 0.03mol/L
Aqueous solution, and strengthened respectively at the 3rd, 7 days, cause osteoarthritis.Start within the 14th day after modeling administration, each group dosage
It is as follows：Normal group and model group, give normal saline gavage 1mL/100g body weight；Glucosamine group, glucosamine 0.16g
Plus 100mL normal salines are into suspension, gavage 1mL/100g body weight is given；Medicine group of the present invention, the embodiment 1 of 0.01g
Medicine add 1000mL normal salines into suspension, give gavage 1mL/100g body weight.1 times/day, successive administration 30d makes
Draw materials within the 49th day after mould.
ELISA method detection IL-4
At the 49th day by after death, the blood sampling of row ventral aorta, by institute blood sampling 3000r/min centrifugation 5min, takes blood at animal
Clearly, -80 DEG C of Refrigerator stores are put to be measured.Concrete operation step presses test kit, and (IL-4ELISA test kits are purchased from the enzyme-linked biological section in Shanghai
Skill company limited) description carries out.As a result see the table below.
| Group | IL-4(pg·mL-1) |
| Normal group | 172.89±11.25 |
| Model group | 45.16±8.28 |
| Glucosamine group | 92.32±10.25 |
| Medicine group of the present invention | 95.40±9.77 |
As seen from the above table, the glucosamine group (P that compares that there was no significant difference with the effect of medicine group of the present invention>0.05).
Claims (7)
1. a kind of pharmaceutical composition for treating knee joint osseous arthritiies, it is characterised in that described pharmaceutical composition includes following formula
Compound or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
Wherein
R1 independently selected from：H or halogen；
R2 independently selected from：H, alkyl or halogen.
2. it is according to claim 1 treatment knee joint osseous arthritiies pharmaceutical composition, it is characterised in that R1 is Cl.
3. it is according to claim 2 treatment knee joint osseous arthritiies pharmaceutical composition, it is characterised in that R2 is CH3。
4. it is according to claim 3 treatment knee joint osseous arthritiies pharmaceutical composition, it is characterised in that the medicine
Compositionss can make tablet etc..
5. purposes of the compound in the medicine for preparing treatment knee joint osseous arthritiies, it is characterised in that compound tool
There is having structure：
Wherein
R1 independently selected from：H or halogen；
R2 independently selected from：H, alkyl or halogen.
6. purposes according to claim 5, it is characterised in that R1 is Cl.
7. purposes according to claim 6, it is characterised in that R2 is CH3。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710087011.1A CN106580967A (en) | 2017-02-17 | 2017-02-17 | Medicine composition for treating KOA (knee osteoarthritis) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710087011.1A CN106580967A (en) | 2017-02-17 | 2017-02-17 | Medicine composition for treating KOA (knee osteoarthritis) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106580967A true CN106580967A (en) | 2017-04-26 |
Family
ID=58587547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710087011.1A Withdrawn CN106580967A (en) | 2017-02-17 | 2017-02-17 | Medicine composition for treating KOA (knee osteoarthritis) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106580967A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498511A (en) * | 2018-04-21 | 2018-09-07 | 徐晶 | A kind of pharmaceutical composition and preparation method thereof for treating knee joint osseous arthritis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884804B2 (en) * | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| CN105348171A (en) * | 2015-12-08 | 2016-02-24 | 彭冬青 | Pharmaceutical composition for treating knee osteoarthritis |
| CN106164069A (en) * | 2014-03-28 | 2016-11-23 | 住友化学株式会社 | Terazololine-one compound and application thereof |
-
2017
- 2017-02-17 CN CN201710087011.1A patent/CN106580967A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884804B2 (en) * | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| CN106164069A (en) * | 2014-03-28 | 2016-11-23 | 住友化学株式会社 | Terazololine-one compound and application thereof |
| CN105348171A (en) * | 2015-12-08 | 2016-02-24 | 彭冬青 | Pharmaceutical composition for treating knee osteoarthritis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498511A (en) * | 2018-04-21 | 2018-09-07 | 徐晶 | A kind of pharmaceutical composition and preparation method thereof for treating knee joint osseous arthritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112538456B (en) | Multipotent stem cell, pharmaceutical composition, and preparation method and application thereof | |
| AU2022202684A1 (en) | Compounds, devices, and uses thereof | |
| BRPI0414455A (en) | Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders | |
| CN101874031A (en) | Sirtuin modulating imidazothiazole compounds | |
| CN101801981A (en) | Plucked instrument soil is because of modulability thiazole and pyridine compounds | |
| CN103301149B (en) | Medicinal preparation capable of increasing bone mineral density and improving osteoporosis | |
| JP2021120409A (en) | Pharmaceutical association for converting neoplastic cell into non-neoplastic cell and uses thereof | |
| WO2019195056A1 (en) | Methods, compositions, and implantable elements comprising stem cells | |
| JP2021138720A (en) | Pharmaceutical association for converting neoplastic cell into non-neoplastic cell and uses thereof | |
| WO2013174863A1 (en) | Chondroitin for use in medicine | |
| CN106580967A (en) | Medicine composition for treating KOA (knee osteoarthritis) | |
| KR20180050744A (en) | Pharmaceutical associations for converting neoplastic cells into non-neoplastic cells and uses thereof | |
| CN1466994A (en) | Compositions and therapeutic use | |
| WO2017215349A1 (en) | Use of mogrol in preparation of drugs for hepatic fibrosis | |
| WO2009113512A1 (en) | Socs3 expression promoter, drug and food containing the same and method of promoting the expression of socs3 | |
| BR112022007413A2 (en) | METHODS TO STIMULATE THE PRODUCTION OF ONE OR MORE FATTY ACIDS, TO INHIBIT THE GROWTH OF ONE OR MORE BACTERIAL PHYLA, TO PROMOTE GASTROINTESTINAL HEALTH, THE GROWTH OF ONE OR MORE BACTERIAL FILA, INTEGRITY OF THE INTESTINAL BARRIER AND AN INTESTINAL PHENOTYPE AND TO TREAT OR PREVENT PARKINSON'S DISEASE | |
| JP6778200B2 (en) | Compositions Containing Spiranthes sinensis Extract and Pharmaceutical Applications thereof | |
| KR20080009695A (en) | Healthfood and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| NZ597657A (en) | Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections | |
| JP2007262103A (en) | Remedy for osteoarthritis | |
| CN107840897A (en) | It is a kind of to be used to treat hyaluronic acid magnesium salts of osteoarthritis and its preparation method and application | |
| CA2573741A1 (en) | Use of organic glucosamine salts | |
| CN106822876A (en) | A kind of medicine for blocking gonitis articular cartilage damage patient's inflammatory factor | |
| CN101485685B (en) | Application of mesenchymal stem cells in preparing medicament for treating autoimmune disease | |
| JP4041856B2 (en) | Treatment for osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170426 |
|
| WW01 | Invention patent application withdrawn after publication |